Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH4502 Monotherapy in Advanced Solid Tumors Expressing Nectin-4
NCT06781983Phase 1Active, not recruiting
- Sponsor
- Innate Pharma
- Start
- Jan 2025
- Primary completion
- Apr 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of iph4502 in solid tumor, sponsored by Innate Pharma. Primary endpoint: Safety and Tolerability at 24 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
iph4502
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06781983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781983.